- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:02 | Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 179 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the... ► Artikel lesen | |
| Mo | OS Therapies sets up subsidiary to seek ADC joint ventures with US, China peers | 2 | FierceBiotech | ||
| Mo | OS Therapies gründet Tochtergesellschaft für Fortschritte bei Krebsmedikamenten | 1 | Investing.com Deutsch | ||
| Mo | OS Therapies creates subsidiary for cancer drug advances | 1 | Investing.com | ||
| 14.02. | Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer | 2 | Benzinga.com | ||
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 14.02. | OS Therapies bereitet sich auf FDA-Treffen zu Krebsmedikament vor | 2 | Investing.com Deutsch | ||
| 14.02. | OS Therapies gears up for FDA meeting on cancer drug | 1 | Investing.com | ||
| 04.02. | OS Therapies gears up for osteosarcoma drug approval | 1 | Investing.com | ||
| 04.02. | OS Therapies bereitet sich auf die Zulassung eines Osteosarkom-Medikaments vor | 1 | Investing.com Deutsch | ||
| 31.01. | OS Therapies announces offering of 10.83M shares by selling stockholders | 1 | Seeking Alpha | ||
| 31.01. | OS Therapies Inc - S-1, General form for registration of securities | - | SEC Filings | ||
| 29.01. | OS Therapies pays $8M for full IP rights to its lead drug, gains 2 more cancer assets in the process | 1 | FierceBiotech | ||
| 29.01. | OS Therapies Expands Pipeline With Ayala Asset Acquisition, Stock Up | - | RTTNews | ||
| 29.01. | OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline | 120 | Business Wire | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced... ► Artikel lesen | |
| 29.01. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 15.01. | Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday? | 1 | Benzinga.com | ||
| 15.01. | OS Therapies' HER2 drug prevented lung cancer from returning in a 3rd of patients | 2 | FierceBiotech | ||
| 15.01. | Pre-market Movers: Safe & Green Holdings, OS Therapies, Vision Marine Technologies, Giftify, Millennium Group International | 824 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Safe & Green Holdings Corp. (SGBX) is up over 155%... ► Artikel lesen | |
| 15.01. | OS Therapies up 65% as lung osteosarcoma asset meets goal in phase 2 trial | 2 | Seeking Alpha | ||
| 15.01. | OS Therapies-Aktie steigt nach Erfolg in Phase-2b-Studie stark an | 3 | Investing.com Deutsch |
Seite:
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 42,600 | +1,43 % | CEO von CRISPR Therapeutics verkauft Aktien im Wert von 1,01 Millionen US-Dollar | ||
| IMMUNIC | 1,110 | +2,59 % | EQS-News: Immunic AG: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Conference/Study
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
26.02.2025... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,380 | -7,69 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series | Marlborough, Massachusetts--(Newsfile Corp. - February 26, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,810 | +4,60 % | EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics | CANBERA (dpa-AFX) - Biotechnology firm CSL Ltd. (CSL.AX, CMXHF.PK) and sa-mRNA pioneer Arcturus Therapeutics Ltd. (ARCT) announced Friday that the European Commission has granted marketing authorization... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,293 | +2,60 % | Chiesi Global, Protalix Announce EMA Validation Of Variation Submission For Pegunigalsidase Alfa | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chiesi Global Rare Diseases, a unit of Chiesi Group, and Protalix BioTherapeutics announced the European Medicines Agency has validated the Variation Submission... ► Artikel lesen | |
| MEIRAGTX | 6,650 | -0,75 % | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy | As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved... ► Artikel lesen | |
| INVIVYD | 1,145 | -7,29 % | Invivyd, Inc.: FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA (pemivibart) | FDA's reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody (mAb) must meet a standard of superior antiviral activity rather than equivalent... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 0,535 | -4,87 % | Unicycive Therapeutics, Inc.: Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update | - OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025- - Commercial Planning in Progress for 2025 Launch - - Late Breaker Poster Presentation... ► Artikel lesen | |
| QIAGEN | 36,830 | -1,17 % | ANALYSE-FLASH: Berenberg senkt Ziel für Qiagen auf 48 Euro - 'Buy' | HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 54,90 auf 48,00 Euro gesenkt und die Einstufung auf "Buy" belassen. Das vierte Quartal sei solide gewesen, auch wenn... ► Artikel lesen | |
| TEMPUS AI | 56,17 | +1,68 % | Tempus AI Aktie: Langfristige Planung vorgestellt | Der Technologiekonzern Tempus AI verzeichnet derzeit bemerkenswerte Bewegungen im Aktienhandel, wobei mehrere hochrangige Führungskräfte in der vergangenen Woche umfangreiche Aktienverkäufe tätigten.... ► Artikel lesen | |
| EVOTEC | 8,185 | -3,93 % | Evotec Aktie: Die gegenwärtige Marktlage analysiert | Die Evotec-Aktie zeigte sich am Handelstag in einer wechselhaften Verfassung, konnte aber letztlich eine positive Tendenz verzeichnen. Im XETRA-Handel markierte das Papier ein Tageshoch von 8,78 Euro... ► Artikel lesen | |
| BIONTECH | 106,80 | -1,57 % | Überflieger 2025: Valneva, BioNTech oder CureVac? | Biotech-Aktien von Valneva, BioNTech oder Curevac konnten nach langen Durstsrecken in den letzten Monaten wieder Momentum generieren und neue Anleger gewinnen. Allen voran der französische Impfstoffentwickler... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 57,75 | +8,23 % | Assessing SpringWorks Therapeutics: Insights From 6 Financial Analysts | ||
| RECURSION PHARMACEUTICALS | 7,510 | -2,21 % | Recursion Pharmaceuticals: Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results | Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous... ► Artikel lesen | |
| ARCELLX | 64,91 | +5,70 % | Arcellx GAAP EPS of -$2.00 misses by $0.40, revenue of $107.94M |
OS THERAPIES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,070 (-4,17 %) liegt der Kurs bei 1,610 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.
